Kinaset Therapeutics
Pre-clinicalDEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
Founded
2020
Focus
Small Molecules
About
DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
Funding History
2Total raised: $112M
Series B$72MF-Prime CapitalJan 15, 2023
Series A$40MAtlas VentureApr 15, 2021
Company Info
TypePrivate
Founded2020
LocationBoston, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile